Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV)
ID: 359860Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359860
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Multidisciplinary Research to Accelerate Hepatitis B Cure in Persons Living with HIV and HBV (MRA-HBV) program, aimed at advancing research in the field of infectious diseases. This initiative seeks to support innovative research that elucidates mechanisms of persistence and pathogenesis of Hepatitis B, develops clinically relevant biomarkers, identifies new drug targets, and creates non-invasive diagnostics, leveraging existing clinical data and sample repositories. With an estimated total program funding of $8 million and the expectation of awarding two grants, interested small businesses should note that the application process is open, with key deadlines including an estimated synopsis close date of August 19, 2026, and an anticipated award date of March 1, 2027. For further inquiries, applicants can contact Josh Radke, Ph.D., at josh.radke@nih.gov or by phone at 301-761-6525.

    Point(s) of Contact
    Josh Radke, Ph.D. National Institute of Allergy and Infectious Disease (NIAID)
    (301) 761-6525
    josh.radke@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Martin Delaney Collaboratories for HIV Cure Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Martin Delaney Collaboratories for HIV Cure Research," aimed at advancing research strategies to control HIV replication and ultimately eradicate HIV reservoirs. This initiative seeks to foster collaborations among academic institutions, government scientists, the private sector, and community stakeholders to accelerate HIV cure research, particularly addressing the needs of children living with HIV. The estimated total program funding is $20 million, with six awards expected to be granted, and interested small businesses can reach out to Diane Lawrence, Ph.D., at diane.lawrence2@nih.gov or call 240-627-3202 for more information. Key deadlines include an estimated synopsis post date of April 21, 2026, and a close date of August 19, 2026, with awards anticipated by March 1, 2027.
    Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)" aimed at supporting the development of broadly protective vaccines for hepatitis C virus (HCV). This initiative seeks to establish a consortium of Research Centers that will focus on the design, optimization, evaluation, and advancement of vaccine candidates into clinical trials, encouraging collaborative investigations among experts in HCV vaccine development. The estimated total program funding is $8.3 million, with four awards expected, and interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published on July 7, 2025. For further inquiries, potential applicants can contact Dr. Rajeev Gautam at rajeev.gautam@nih.gov or by phone at 301-761-5347.
    Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research." This initiative aims to support the secondary use of archived data and biospecimen collections to enhance research in maternal, pediatric, and adolescent HIV, encouraging the integration of innovative data science methods and interdisciplinary approaches. With an estimated total program funding of $1,000,000 and the expectation of awarding two grants, interested small businesses can reach out to Samantha Calabrese at samantha.calabrese@nih.gov or call 301-827-7568 for more information. Key deadlines include an estimated synopsis post date of October 1, 2025, and a closing date of January 2, 2026, with project start and award dates anticipated for July 1, 2026.
    Implementation Science to End the HIV Epidemic
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Implementation Science to End the HIV Epidemic," aimed at advancing efforts to combat HIV through innovative research-community collaborations. The initiative seeks projects that will develop and evaluate strategies for HIV prevention, diagnosis, treatment, and outbreak response, particularly in communities disproportionately affected by the epidemic. This funding, totaling an estimated $7 million, will support approximately 10 awards, with applications open to a diverse range of eligible entities, including tribal governments, federal agencies, and community-based organizations. Interested applicants should note that the estimated synopsis close date is April 17, 2026, and the anticipated award date is December 1, 2026; for further inquiries, contact Rebecca Mandt, Ph.D., at rebecca.mandt@nih.gov or call 301-435-7695.
    NIAID Investigator Initiated Program Project Applications
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is inviting applications for the Investigator Initiated Program Project Grants aimed at advancing research in areas pertinent to the NIAID mission. This program encourages small businesses to propose innovative projects that explore the biology and pathogenesis of microbes, immune system functions, and the development of vaccines and therapeutics for infectious and immune-mediated diseases. The grant does not require cost-sharing or matching, with an estimated award date set for December 1, 2026, and applications are due by January 25, 2026. For further inquiries, interested applicants can contact Dr. Chelsea Boyd at chelsea.boyd@nih.gov or by phone at 301-761-6664.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at exploring innovative HIV cure strategies at the initiation of combination antiretroviral therapy (cART). This initiative seeks to identify and develop interventions that can be applied at the start of cART or following treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The funding, available for up to two years with a maximum budget of $275,000, is open to a diverse range of eligible applicants, including higher education institutions, non-profits, and for-profit entities. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline set for September 7, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) intends to publish a Notice of Funding Opportunity (NOFO) for the Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required). This initiative aims to solicit applications for research focused on liver cirrhosis, specifically to complete enrollment in ongoing studies, including the Liver Cirrhosis Network Longitudinal Cohort Study and the RESCU clinical trial. The program is significant for advancing understanding and treatment of liver diseases, with an estimated total funding of $3,302,147 and an award ceiling of $330,214, anticipating approximately 10 awards. Interested applicants, particularly small businesses with expertise in liver disease research, are encouraged to prepare for application submission, with the estimated synopsis post date on July 11, 2025, and a closing date of August 15, 2025. For further inquiries, contact Edward Doo, MD, at dooe@niddk.nih.gov or call 301-451-4524.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
    NIAID Resource-Related Research Projects
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "NIAID Resource-Related Research Projects," aimed at supporting investigator-initiated research that develops essential resources for biomedical research. This program encourages small businesses to propose non-hypothesis-driven activities that provide high-quality data, materials, tools, or services relevant to the NIAID mission, which includes areas such as infectious diseases, immune function, and translational research for vaccines and therapeutics. Interested applicants should note that there is no cost-sharing requirement, and the estimated synopsis close date is January 26, 2026, with awards expected to be made by December 1, 2026. For further inquiries, applicants can contact Dr. Chelsea Boyd at chelsea.boyd@nih.gov or by phone at 301-761-6664.
    Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)." This initiative aims to solicit research applications focused on the preclinical development of lead candidate vaccines to combat Mycobacterium tuberculosis (Mtb) infection and disease, thereby enhancing the clinical pipeline of viable vaccine candidates. The program is critical for advancing public health efforts against tuberculosis, a significant global health challenge. The estimated total funding for this program is $4,730,000, with approximately five awards expected. Interested applicants can reach out to Katrin Eichelberg, MSc, PhD, at keichelberg@nih.gov or call 240-669-2921 for further information. Key deadlines include an estimated synopsis post date of September 8, 2025, and a close date of November 7, 2025, with awards anticipated to be made by July 1, 2026.